"The US Food and Drug Administration (FDA) has approved Akorn Inc's phenylephrine hydrochloride ophthalmic solution (2.5% and 10%), the company has announced.
The alpha-1 adrenergic receptor agonist is commonly used by optometrists, ophtha"...
DOSAGE AND ADMINISTRATION
The recommended dose is one drop of OptiPranolol (metipranolol ophthalmic solution) Ophthalmic Solution in the affected eye(s) twice a day.
If the patient's IOP is not at a satisfactory level on this regimen, use of more frequent administration or a larger dose of OptiPranolol (metipranolol ophthalmic solution) Ophthalmic Solution is not known to be of benefit. Concomitant therapy to lower intraocular pressure can be instituted.
OptiPranolol® (metipranolol ophthalmic solution) 0.3% is supplied in a plastic bottle with a controlled drop tip and a yellow plastic screw-top cap as follows:
5 mL: NDC 24208-275-07 - AB40207
10 mL: NDC 24208-275-09 - AB40209
Store between 15° - 30° C (59° - 86° F). Replace cap immediately after use.
DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.
FOR OPHTHALMIC USE ONLY.
Bausch & Lomb Incorporated, Tampa, FL 33637. REV. 11/03-91. FDA rev date: 11/21/2006This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/13/2008
Additional Optipranolol Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.